Baseline characteristics of patients
| Parameters . | Results (n=60) . |
|---|---|
| Demographics | |
| Median age | 60 y (range: 26-81) |
| Female gender | 63.3% (n = 38) |
| CML at diagnosis | |
| Chronic phase | 100% (n = 60) |
| Sokal risk group | |
| Low | 53.3% (n = 32) |
| Intermediate | 26.7% (n = 16) |
| High | 15% (n = 9) |
| Unknown | 5% (n = 3) |
| Cytogenetics | |
| Ph1 without ACAs | 93.2% (n = 56) |
| Ph1 with ACAs | 3.4% (n = 2) |
| Unknown | 3.4% (n = 2) |
| M-bcr transcript type | 100% (n = 60) |
| Treatment history | |
| Prior IFN-α | 28.3% (n = 17) |
| 1st line dasatinib or nilotinib | 13.3% (n = 8) |
| 2nd line dasatinib or nilotinib | 66.7% (n = 40) |
| 3rd line dasatinib or nilotinib | 20% (n = 12) |
| Intolerance to imatinib | 65% (n = 39) |
| Suboptimal response or resistance to imatinib | 21.7% (n = 13) |
| Imatinib-resistant BCR-ABL1 mutation* | 30.8% (n = 4) |
| No mutation | 53.8% (n = 7) |
| Mutation status unknown | 15.4% (n = 2) |
| Median duration of TKI therapy | 76 mo (range: 36-153) |
| Median duration of 2G-TKI treatment | 39 mo (range: 19-83) |
| Median duration of uMR4.5 | 29 mo (range: 24-64) |
| Treatment discontinuation | |
| Dasatinib | 50% (n = 30) |
| Nilotinib | 50% (n = 30) |
| Parameters . | Results (n=60) . |
|---|---|
| Demographics | |
| Median age | 60 y (range: 26-81) |
| Female gender | 63.3% (n = 38) |
| CML at diagnosis | |
| Chronic phase | 100% (n = 60) |
| Sokal risk group | |
| Low | 53.3% (n = 32) |
| Intermediate | 26.7% (n = 16) |
| High | 15% (n = 9) |
| Unknown | 5% (n = 3) |
| Cytogenetics | |
| Ph1 without ACAs | 93.2% (n = 56) |
| Ph1 with ACAs | 3.4% (n = 2) |
| Unknown | 3.4% (n = 2) |
| M-bcr transcript type | 100% (n = 60) |
| Treatment history | |
| Prior IFN-α | 28.3% (n = 17) |
| 1st line dasatinib or nilotinib | 13.3% (n = 8) |
| 2nd line dasatinib or nilotinib | 66.7% (n = 40) |
| 3rd line dasatinib or nilotinib | 20% (n = 12) |
| Intolerance to imatinib | 65% (n = 39) |
| Suboptimal response or resistance to imatinib | 21.7% (n = 13) |
| Imatinib-resistant BCR-ABL1 mutation* | 30.8% (n = 4) |
| No mutation | 53.8% (n = 7) |
| Mutation status unknown | 15.4% (n = 2) |
| Median duration of TKI therapy | 76 mo (range: 36-153) |
| Median duration of 2G-TKI treatment | 39 mo (range: 19-83) |
| Median duration of uMR4.5 | 29 mo (range: 24-64) |
| Treatment discontinuation | |
| Dasatinib | 50% (n = 30) |
| Nilotinib | 50% (n = 30) |
BCR-ABL1 kinase domain mutations: A387P (n = 1), M244V (n = 2), and H396R + F359V (n = 1).